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Abstract Pediatric patients with Down syndrome (DS)
are at an increased risk of developing certain cancers.
Specifically, patients with DS have a reported 10–20-fold
increased risk of developing acute myeloid leukemia
(AML). Anthracycline-based treatment regimens achieve
good results in patients with DS and AML. It has been
proposed that DS status constitutes a risk factor for the
cardiotoxicity associated with the use of anthracyclines in
the pediatric setting. However, published evidence pointing
toward an increased risk of cardiotoxicity in patients with
DS is relatively scarce and conflictive. This concise review
compiles literature relating to the incidence of anthracycline-related cardiotoxicity in pediatric patients with DS. In
general, reports from trials using anthracyclines at the
maximum recommended dose showed increases in the
incidence of anthracycline-related cardiotoxicity in patients
with DS in comparison with trials that used anthracyclines
at reduced doses. Evidence from the literature suggests that
patients with DS can achieve favorable therapeutic outcomes after receiving treatment with reduced doses of
anthracyclines to minimize the potential for cardiotoxicity.
Further prospective trials, along with the available evidence, would assist the design of treatment protocols for
patients with pediatric leukemias and DS.
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Introduction
Children with Down syndrome (DS) have a 10–20-fold
increase in the incidence of acute myeloid leukemia (AML)
as compared to patients without DS [1, 2]. Patients with DS
and AML are treated with anthracycline-based chemotherapeutic regimens that typically include doxorubicin,
daunorubicin, or idarubicin. In general, the treatment for
pediatric AML can be divided in two main phases:
induction and consolidation. Most chemotherapeutic
regimes incorporate anthracyclines during the induction
phase at varying dose intensities. Cytarabine-based therapy
and/or other approaches such as allogenic stem cell transplants are utilized during the consolidation phase [3].
Chemotherapy regimens in patients with DS and AML are
efficacious and often result in superior therapeutic endpoints as compared to patients with AML and without DS
[4–7]. Leukemic cells from patients with DS have
increased sensitivity to the cytotoxic effects of anthracycline chemotherapeutics which may contribute to more
effective elimination of the leukemia [6]. Unfortunately,
the clinical use of anthracyclines is limited by the development of adverse side effects in some patients. Anthracyclines can trigger various adverse side effects such as
immunosuppression, nausea, and mucositis. These toxicities are shared with other chemotherapeutic agents. Anthracyclines can also cause dose-limiting cardiotoxicity. The
cardiotoxicity exerted by anthracyclines spans a spectrum
of signs and symptoms ranging from relatively minor
perturbations in cardiac rhythm and myocardial function to
severe cardiomyopathy and congestive heart failure (CHF)
[8]. The incidence of CHF secondary to anthracyclineinduced cardiomyopathy is related to the total cumulative
dose of the drug, and an empirically determined threshold
of 300–500 mg/m2 has often been used for adult patients.
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Reports have shown that children treated with higher
cumulative doses (especially children exposed to [300
mg/m2) are at increased risk of subclinical cardiovascular
dysfunction and clinically significant cardiomyopathy [9].
These data have not been helpful for selecting an appropriate dose for individual patients, given that doses in
excess of 1,000 mg/m2 have been well tolerated by some
patients, whereas a dose as low as 150 mg/m2 has resulted
in a significant decrease in the left ventricular ejection
fraction and other signs of cardiac toxicity (e.g., arrhythmias) in others [10, 11].
The cardiotoxicity of anthracycline chemotherapeutic
agents is mediated by a combination of different mechanisms. Anthracyclines are metabolized to alcohol metabolites that can disrupt iron and calcium homeostasis in the
cardiomyocytes via interactions with iron(II) and the calcium transporter SERCA2, respectively. Anthracyclines
can cause an irreversible decrease in mitochondrial Ca?2
loading and ATP content. This, when combined with
impairment of mitochondrial creatine kinase activity, can
lead to mitochondrial dysfunction in the cardiomyocyte.
Anthracyclines can also cause mitochondrial dysfunction
due to increased generation of reactive oxygen species in
cardiac mitochondrion [12, 13]. The oxidative stress triggered by anthracyclines is not effectively controlled in
cardiomyocytes due to decreased levels of detoxifying
enzymes such as superoxide dismutase [14]. Anthracycline
treatment can also alter nitric oxide regulation in the cardiomyocyte and lead to the disruption of normal heart
function [15].
Since 15 % of all pediatric patients with AML have DS,
many of the clinical trials have focused on the outcomes
and efficacy of AML treatments [16]. However, when
considering the reported data on treatment-related toxicity
in patients with DS and AML, there are discrepancies
between the published reports. Specifically, the incidence
of anthracycline-related cardiotoxicity in patients with DS
and AML has not been reported in a consistent manner.
Often, the analysis of anthracycline-related cardiotoxicity
in patients with DS and AML has not been a primary aim
of the studies; therefore, the data were not detailed and
rarely included quantitative estimates of prevalence. The
purpose of this concise review is to explore the published
literature in an attempt to shed light on the following
question ‘‘Do pediatric patients with AML and DS treated
with anthracyclines experience more or less cardiotoxicity
than equally treated patients with AML and without DS?’’

Literature Analysis
Published reports that consider anthracycline-based therapy
for pediatric patients (i.e., patients under the age range of
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18–21 years old) with AML were considered for inclusion
in this manuscript. Specifically, articles that reported data
on incidences of anthracycline-related cardiotoxicity in
pediatric patients with DS and AML were considered for
this review. The online databases PubMed and OVID
Medline were searched using the keywords ‘‘Down syndrome,’’ ‘‘cardiotoxicity,’’ ‘‘anthracycline,’’ ‘‘pediatric,’’
‘‘acute myeloid leukemia,’’ ‘‘daunorubicin,’’ ‘‘doxorubicin,’’ ‘‘adriamycin,’’ and ‘‘AML’’ between August 15 and
September 15, 2014. This search resulted in 16 primary
peer-reviewed articles for analysis that either focused on
cardiotoxicity in patients with DS that received anthracycline-based therapy or reported cardiotoxicity as an adverse
effect in a clinical study. These reports were published
between 1990 and 2012, and the patient data presented
ranged from the early 1970s to the 2000s. Other primary
literature that discussed cardiotoxicity in pediatric patients
with DS and AML were also considered. The published
primary reports utilized in this review are summarized and
compiled in Table 1.

Studies that Suggest Elevated Relative Incidence
of Anthracycline-Related Cardiotoxicity in Patients
with DS
One of the first reports to examine the treatment and outcomes of children with DS and leukemia that also mentioned anthracycline-related cardiotoxicity was published
by Levitt et al. [17] in 1990 (Table 1). In this study, 90
patients under 15 years of age with DS and either AML or
acute lymphoblastic leukemia (ALL) were recruited and
treated with the UKALL X protocol. The study did not aim
to measure the incidence of anthracycline-related cardiotoxicity directly. The authors mentioned that irreversible
cardiomyopathy was seen in two out of a total of 26
patients with DS and AML. Both patients died while off
treatment due to unspecified cardiomyopathy presumably
associated with daunorubicin. It was noted that one patient
had a normal electrocardiogram (EKG), while the other had
a heart defect. One of the children with fatal cardiomyopathy had been re-treated with daunorubicin due to bone
marrow relapse. The authors did not set the criteria used to
determine cardiotoxicity, and the dose of anthracycline was
not specified [17].
Arguably, one of the first reports that established DS
status as a significant risk factor for anthracycline-related
cardiotoxicity was published in 1997 by Krischer et al. [1].
The report was a retrospective analysis that compiled data
on 6,493 children with and without DS and with various
types of cancer (e.g., leukemias, sarcomas, and brain
tumors) who had received anthracycline chemotherapy per
protocols from the Pediatric Oncology Group (POG) from

First author

Levitt

Ravindranath

Creutzig

Krischer

Craze

Kojima

Gamis

Creutzig

Protocol

UKALL X

POG 8498

AML-BFM 87/93

POG protocols
1974–1990

AML-10, other
recognized
intensive
protocols,
individualized
protocols

Institutional
specific AMLDown protocol

CCG 2891

AML-BFM 93/98

2005

2003

2000

1999

1997

1996

1992

1990

Year

Cumulative anthracycline
dose for DS–AML
patients =
220–240 mg/m2, for
non-DS–AML
patients =
320–450 mg/m2

118

161

Daunorubicin 20 mg/m2 days 0–4,
4 cycles (320 mg/m2
cumulative dose)

Cardiotoxicity,
standard
chemotherapy
patients: 2 %
Cardiotoxicity:
1 (0.08 %)

Cardiotoxicity,
intensive
chemotherapy
patients: 1 %

Cardiotoxicity: 2
(6.1 %)

33

Mean anthracycline (daunorubicin,
pirarubicin, or mitoxantrone)
dose = 300 mg/m2

Cardiotoxicity: 4
(6 %)

66

Cardiomyopathy or
decreased cardiac
function: 9 (20 %)

Cardiotoxicity: 2
(9.5 %)

No incidences
reported

12

21

Cardiomyopathy: 2
(7.6 %)

26

907

947

0

114

6,427

589

273

713

Cardiotoxicity,
standard
chemotherapy
patients: 1 %
Cardiotoxicity
not reported
or mentioned
in this group

Cardiotoxicity,
intensive
chemotherapy
patients: 4.5 %

Not considered
in the study

Cardiotoxicity not
reported or
mentioned
in this group

Cardiotoxicity: 102
(1.6 %)

Cardiotoxicity not
reported or
mentioned in this
group

No incidences
reported

Cardiotoxicity not
reported or
mentioned
in this group

Reported
cardiotoxicity

n

n

Reported
cardiotoxicity

Patients without DS with AML

Patients with DS and AML

45

Doxorubicin, daunorubicin, or
mitoxantrone at a cumulative
dose up to 550 mg/m2
Anthracycline dose based on
protocol used

Cumulative anthracycline dose
(doxorubicin and daunorubicin)
was 220–400 mg/m2

Cumulative anthracycline
(daunorubicin) dose =
225 mg/m2, induction only)

Daunorubicin dose
not specified

Anthracycline dose

Table 1 Summary of select published studies that report cardiotoxicity in pediatric patients with DS and AML

The patient who experienced late
cardiotoxicity received a cumulative
anthracycline dose of * 400
mg/m2

Nonsignificant difference in the grade
III/IV cardiac toxicity rates in AML
patients with DS vs. patients without
DS

The two individuals died of
congestive heart failure, one during
consolidation, the other after
38 months in remission

Four of the patients with DS
experienced cardiac failure, one
patient died

The relative risk of cardiotoxicity was
3.37 (p = 0.02)

One patient had cardiac failure and
the other died of congestive heart
failure in remission

It was noted that 50 % of DS patients
had congenital heart defects, but that
did not affect unreported
cardiotoxicity

Both children had irreversible
cardiomyopathy, one had a
congenital defect, one had a normal
EKG, both died while off treatment

Summarized cardiotoxicity details
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Zeller

Rao

Abildgaard

Creutzig

Kudo

O’Brien

Taga

Sorrell

NOPHO-AML84,
NOPHO-AML88
and
NOPHOAML93

MRC AML-10,12

NOPHOAML88,93

AML-BFM 93/98

AML 99

POG 9421

JCCLSG AML
9805

COG A2971

2012

2011

2008

2007

2007

2006

2006

2005

Year

46

Cumulative 300 mg/m2
daunorubicin,
50 mg/m2 mitoxantrone

Early-onset
cardiomyopathy: 3
(4.1 %), Late-onset
cardiomyopathy: 2
(2.9 %)

74
(early)
69
(late)

68

Cumulative anthracycline dose of
300–450 mg/m2

Pirarubicin 25 mg/m2 (cumulative
dose = 250 mg/m2)

Cardiotoxicity
(intensification): 2
(1.7 %)

Cardiotoxicity
(induction): 5
(3.8 %)

131

Cumulative daunorubicin
dose = 20 mg/m2

Cardiotoxicity: 0
(0 %)

24

Pirarubicin 25 mg/m2 on days 2, 4,
then in remission patients:
mitoxantrone 3.5 mg/m2 on days
2–4 and pirarubicin 35 mg/m2 on
day 2

Cardiomyopathy: 10
(17.5 %)

57

Cumulative anthracycline
dose = 535 mg/m2

Cardiotoxicity: 4
(5.9 %)

Cardiotoxicity: 0
(0 %)

Cardiomyopathy: 2
(4.3 %)

Cardiotoxicity was
not reported or
mentioned in this
group

56

Cumulative anthracycline
(doxorubicin, mitoxantrone)
dose = 300–450 mg/m2

62

0

0

565

0

811
(early)
478
(late)

0

822

435

The number of
patients or
toxicity in this
group was not
reported

This group was not
considered for
this study

Cardiomyopathy: 6
(1.1 %)

This group was not
considered for
this study

Late-onset
cardiomyopathy:
14 (2.9 %)

Early-onset
cardiomyopathy:
35 (4.3 %)

This group was not
considered for
this study

Cardiotoxicity not
reported or
mentioned
in this group

Cardiotoxicity not
reported or
mentioned
in this group

Reported
cardiotoxicity

n

n

Reported
cardiotoxicity

Patients without DS with AML

Patients with DS and AML

Anthracycline
dose based on
protocol used

Anthracycline dose

Cardiotoxicity was not specified
beyond ‘‘ [ grade III ’’,
intensification patients did not
receive additional anthracyclines

Cardiotoxicity in patients with DS and
AML not noted

Cardiotoxicity was found to be higher
in the DS group, three deaths were
related to CHF

Cardiotoxicity was seen during
induction, all patients recovered

Cardiotoxicity presented as decreased
shortening fraction and arrhythmia,
no increased cardiotoxicity was seen
in patients with DS and AML

Cardiotoxicity in patients with DS and
AML not noted

One patient died within 5 years of
clinical remission, one died 13 years
post diagnosis of cardiomyopathy

Cardiotoxicity in patients with DS and
AML not noted

Summarized cardiotoxicity details

The above table summarizes the primary literature examined in this review. Only patients that received treatment are included when presenting number of patients (n) and when calculating
cardiotoxicity percentages when not calculated in the original article

First author

Protocol

Table 1 continued

Cardiovasc Toxicol

Cardiovasc Toxicol

1974 to 1990. Patients with cardiac malformations or with
evidence of myocardial dysfunction, arrhythmias, or conduction abnormalities were excluded from the analysis.
From a total of 66 patients with DS, four patients developed congestive heart failure or sudden death associated
with the use of anthracyclines (Table 1). In univariate
analysis, the relative risk conferred by DS status was 3.55
(95 % confidence interval 1.31–9.76, p = 0.01), whereas
multivariate analysis showed a relative risk of 3.37 for the
presence of DS (95 % confidence interval 1.24–9.18,
p = 0.02). It should be noted that this study was one of the
few that specifically concluded that DS was a risk factor for
anthracycline-related cardiotoxicity with statistical significance (p B 0.05). It should also be noted that this study’s
objective was to identify risk factors for anthracyclinerelated cardiotoxicity in patients with DS, which is not a
common goal of many of the reports reviewed. This is the
most cited study presented in this review (approximately
335 citations), which highlights the impact this report has
had on the field of pediatric oncology.
In 1999, Craze et al. conducted a retrospective study that
considered the outcomes of children with DS and AML
treated in the UK between 1987 and 1995. The authors
reported that nine out of the 45 patients (20 %) with DS
and AML exhibited cardiomyopathy or asymptomatic
deterioration of cardiac function, and four of those had
episodes of cardiac failure related to anthracycline use, one
of which was fatal. The criteria for the diagnosis of cardiomyopathy were not defined, and neither doses nor the
type of anthracycline drug were specified. Four patients
(44 %) had congenital heart disease. Statistical analysis for
the cardiomyopathy data was not provided. The authors
noted that follow-up echocardiographic data were incomplete [4].
A more recent report (2008) by O’Brien et al. [18] from
the North American Children’s Oncology Group (COG)
was based on retrospective chart reviews from cases treated
in the POG protocol 942. In POG 9421, echocardiograms
were required at enrollment, before each chemotherapy
cycle, and at the end of therapy. Cardiomyopathy was
defined as clinically symptomatic CHF that required
medical intervention (e.g., diuretics, inotropic therapy, and
afterload reduction) or dilated cardiomyopathy at autopsy.
The report noted a higher incidence of anthracycline-related cardiotoxicity in patients with DS and AML as compared to patients without DS and AML, although statistical
comparisons were not reported. Ten (17.5 %) out of 57
patients with DS and AML developed cardiomyopathy
associated with the use of daunorubicin and three patients
died of CHF (Table 1). Fifty percent of the patients with
symptomatic cardiomyopathy had congenital heart defects,
and the three cardiomyopathy-related deaths occurred in
children with congenital heart defects. The total dose of

daunorubicin for non-infant patients was 135 mg/m2, and
the authors noted that dose adjustments for infant patients
were preformed ‘‘as prescribed’’ [18]. POG 9421 also
included the anthracenedione mitoxantrone (total dose:
80 mg/m2), and the authors reported a total cumulative
exposure to anthracyclines of 535 mg/m2, after using an
empirical 5:1 conversion factor for mitoxantrone.

Studies that do not Suggest Elevated Relative Incidence
of Anthracycline-Related Cardiotoxicity in Patients
with DS
Not all published reports documented increases in the
incidence of anthracycline-related cardiotoxicity in patients
with DS and AML. In 1992, a report by Ravindranath et al.
from the POG highlighted favorable responses to chemotherapy for AML in patients with DS. Although not a
primary endpoint of the study, the authors also touched on
the subject of anthracycline-related cardiotoxicity. However, the criteria for reporting cardiotoxicity were not
specified. The study did not show increased cardiotoxicity
in patients with DS and AML treated with daunorubicin at
a total cumulative dose of 225 mg/m2 (Table 1). The
authors acknowledged that follow-up toxicity data were
limited [19].
In 1996, Creutzig et al. reported the outcomes of 40
patients with DS and AML, 21 of which were treated with
chemotherapy according to protocols by the German cooperative group AML-BFM (Berlin–Frankfurt–Münster). The
authors noted that six patients received major dose or protocol reductions. This study reported cardiac insufficiency in
two patients with AML and DS that were treated with chemotherapy (Table 1). It was noted that one of the patients
received a cumulative anthracycline dose of approximately
400 mg/m2 [20].
In 2000, Kojima et al. conducted a study that included
33 children with DS and AML with the intent to develop a
safe and effective chemotherapeutic regimen for these
patients. The study showed that good results with low
toxicity rates could be achieved with less intensive chemotherapeutic regimens that included mean cumulative
anthracycline doses of 300 mg/m2. In this study, there were
two cases of heart failure noted (Table 1). One patient
received an anthracycline dose of 400 mg/m2 and died
during clinical remission 38 months after therapy, while
the other patient died during consolidation therapy. Of
note, 13 out of the 33 patients were treated with pirarubicin
or mitoxantrone, while the other 20 patients received
daunorubicin. Toxicity was graded with NCI criteria [21].
Gamis et al. [22] reported a 2 % incidence of grade III
or grade IV cardiac toxicity in patients with DS and AML
treated with ‘‘standard-timing’’ induction chemotherapy
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versus a 1 % incidence of cardiac toxicity in the control
group of patients without DS (p = 0.708). In the group of
patients with DS and AML that received intensification of
their chemotherapy regimen (84 % of the total), 1 %
exhibited grade III or grade IV toxicity (Table 1). Grade
III/IV cardiotoxicity was seen in 4.5 % on the patients
without DS (p = 0.148, Table 1). The specifics of the
grading criteria for recording cardiotoxicity were not
reported. Daunorubicin-based induction was used at a dose
of 20 mg/m2/day for the first 4 days of each cycle for four
induction cycles. The result was a 320 mg/m2 total
cumulative dose of daunorubicin. The authors concluded
that patients with DS and AML showed no overall increase
in toxicity when given chemotherapy regimens at a lower
intensity but with an equal total cumulative dose in comparison with patients without DS [22].
In 2005, a second study by Creutzig et al. considered
cure rates of AML in patients with DS treated with AMLBFM protocols 93 and 98. Only one case of clinical cardiotoxicity was noted in the group of 118 patients with DS
and AML (Table 1). The patient who experienced the
cardiotoxicity received a cumulative anthracycline dose of
&400 mg/m2, while the other patients with DS were given
relatively lower doses of anthracyclines (220–240 mg/m2).
The patient was reported to have developed CHF with
progressive cardiomegaly and has been also described in
the previous study [23]. In a population-based study on
patients with leukemia, Zeller et al. [24] considered the
treatment outcomes in a group of 62 patients with DS and
AML. The report did not include any specifics on the
incidence of anthracycline-related cardiotoxicity. The
authors noted that 48 % of the patients with DS were
treated with decreased doses of anthracyclines (Table 1)
[24].
In 2006, Abildgaard et al. reported data on 56 children
with DS treated on the Nordic Society for Pediatric
Hematology and Oncology-acute myeloid leukemia
(NOPHO-AML) protocols NOPHO-AML88 and NOPHOAML93. The authors reported no cardiotoxicity using
protocols that, in general, included cumulative anthracycline doses of 300–450 mg/m2 (Table 1). It was noted that
29 % of the patients with DS were given reduced doses that
were on average 75 % of the scheduled dose of anthracycline. The study did show that patients that were given fulldose anthracycline-based therapy had a higher rate of
treatment-related death [25].
The report by Rao et al. [5] focused on patients with DS
and AML treated in the UK in Medical Research Council
trials AML 10 and AML 12. Patients were treated with
300 mg/m2 of daunorubicin, and two cases of cardiac
failure due to myopathy at 13 and 15 years post-cancer
diagnosis were listed (Table 1). The mortality rate during
the induction phase in patients with DS and AML was
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11 % versus a 4 % mortality rate for the group of patients
with AML and without DS (p = 0.02). Cardiotoxicity was
not listed as a distinct cause of mortality. Criteria and
specifics concerning non-lethal cardiotoxicity were not
discussed [5].
A study in 2007, also conducted by Creutzig et al., is
one of the few reports to consider early- and late-onset
anthracycline-related cardiotoxicity in patients with DS
and AML. The study defined early toxicity as transient
tachycardias, dysrhythmias, or non-specific EKG changes
within 1 year of receiving the anthracycline. Late toxicity
was defined as occurring 1 year after receiving the
anthracycline, and it was characterized by CHF or pericardial effusion. Two out of 69 patients (2.9 %) with DS
and AML showed late cardiotoxicity, and three out of 74
patients (4.1 %) experienced early cardiotoxicity
(Table 1). The patients with early cardiotoxicity showed
reduced shortening fraction and arrhythmias, while the
patients with late cardiotoxicity displayed reduced shortening fraction. One patient developed both early and late
cardiotoxicity after receiving a cumulative anthracycline
dose of over 400 mg/m2. The report noted that liposomal
daunorubicin was used to treat four patients with AML and
without DS [26].
In 2007, a report by Kudo et al. from the Japanese
Childhood AML Cooperative Study Group presented data
from a reduced dose pirarubicin-based chemotherapy regimen on 72 patients (68 of which were assessed for toxicity
during induction) with DS and AML, many of the patients
had acute megakaryocytic leukemia (AMKL). Four individuals (5.9 %) displayed unspecified grade III/IV treatment-related cardiac dysfunction upon induction therapy
(Table 1). It was noted that all of those patients recovered
after the induction phase, but the length of follow-up was
not specified [27]. Likewise, a report from the Japanese
Children’s Cancer and Leukemia Study Group (2011) by
Taga et al. did not document any increased incidence of
undefined grade III/IV cardiotoxicity in a total of 24
patients with DS and AML with a mean follow-up period
of 75 months. In this study, all patients were younger than
4 years of age and had a phenotype of AMKL. The therapy
for remission induction included pirarubicin (25 mg/m2) on
days 2 and 4. The authors noted that reduced anthracycline
doses were used in patients with DS due to the concern for
cardiac insufficiency [28].
A recent report by Sorrell et al. from the COG (2012)
compiled results from the phase 3 trial A2971, the first trial
designed to provide uniform therapy to children with DS
and myeloid leukemia in North America. The A2971
protocol did not include etoposide and dexamethasone in
the induction phase, eliminated the 3 months of systemic
maintenance chemotherapy, which left three intrathecal
doses of cytarabine as maintenance. The study enrolled 132
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patients, 91 patients had DS and AML, and 41 patients had
DS and myelodysplastic syndrome. The total cumulative
dose of anthracycline was 320 mg/m2. Seven individuals
(5.3 %) experienced grade C3 cardiotoxicity, five patients
during the induction phase and two in the intensification
phase. Further details on the cardiotoxicities were not
specified; however, it was mentioned that there was no
difference in the incidence of toxicity in comparison with
the results from the trial CCG 2891. The median follow-up
time was 4.8 years [22, 29].

Conclusions
There are divergent findings in the literature concerning the
incidence of anthracycline-related cardiotoxicity in pediatric patients with DS and AML. There seems to be a trend
toward high-dose or high-intensity conventional anthracycline chemotherapy being linked to increased rates of
cardiotoxicity in patients with DS and AML compared to
patients without DS and AML. Likewise, studies that
showed relatively low incidences of cardiotoxicity tended
to use lower cumulative doses of anthracyclines, anthracyclines with potentially reduced cardiotoxic potential, or
liposomal anthracycline dosage forms. Similar findings
were also reported in studies focused on the chemotherapy
for pediatric patients with ALL and DS. For example,
Bassal et al. [30] reported no increases in grade III or grade
IV cardiotoxicity (NCI CTC 2.0 grading criteria) in
patients with ALL and DS treated with a cumulative dose
of anthracycline of 150 mg/m2 [30]. Other reports involving pediatric ALL patients without DS showed that doses
of anthracyclines [300 mg/m2 significantly increased the
risk of cardiac complications and toxicity [31].
Differences in the specific anthracycline used may
impact the incidence of clinical cardiotoxicity. For example, Japanese trials documented very low cardiotoxicity
associated with the use of pirarubicin, which is reported to
have less cardiotoxic potential compared to doxorubicin or
daunorubicin (Table 1) [27, 28, 32]. Likewise, liposomal
doxorubicin is known to have reduced toxicity (including
cardiotoxicity) which may have impacted the rates of
cardiotoxicity reported by Creutzig et al. [26] [33]. Anthracyclines are very rarely given as monotherapy, and
patients are often exposed to cytotoxic drugs with cardiotoxic potential. The anthracenedione mitoxantrone may
induce cardiotoxicity [34]. The use of mitoxantrone and
other chemotherapeutic agents in the presented studies may
have had an impact on the rates of reported cardiotoxicity.
It is important to consider potential confounders when
comparing different reports, including the demographics of
the patient population. The reports included patients
younger than 18–21 years of age. However, the mean ages

between studies were different. Some reports had patient
populations with mean ages at the high and low ends of the
‘‘pediatric’’ spectrum. For example, the report by Kudo
et al. included infant patients of around 1 year of age, while
57 % of the patients in the report by Krischer et al. [1, 27]
were over 6 years of age. Age discrepancies may be a
confounder when comparing the incidence of toxicities
between protocols, since the susceptibility to specific toxicities might vary with age [31]. It has already been shown
that age can affect clinical outcomes in patients with leukemia and DS, so it is reasonable to suspect that age may
be also a factor when considering the risk of anthracyclinerelated toxicity in this group of subjects [22, 25]. The
definition of cardiac toxicity is another potential confounding factor when comparing data from various studies.
Some of the studies did not contain explicit definitions for
the terms cardiotoxicity or cardiac dysfunction, while
others used grading systems based on combinations of
symptoms and objective measurements that may not
communicate the specific nature of the cardiac dysfunction
to the reader. There are different grading criteria available,
and the use of unspecified grading systems in some studies
makes comparison difficult [35]. Depending on the study,
early- or late-onset cardiotoxicity may not be accounted
for, or differentiated. Often, the reports noted relatively
limited follow-up periods that may have been inadequate to
capture late-onset cardiotoxicity [36]. This leads to the
possible issue of underreporting the incidence of cardiotoxicity in patients with DS and leukemia, as put forth by
O’Brien et al. [18]. Few reports have included comparative
cardiotoxicity data from patients with and without DS and
AML, which precludes the exploration of potential differences in susceptibility between groups. Some studies
focused on treatment efficacy in patients with DS and
leukemia have not included data or comments on the topic
of anthracycline-related cardiotoxicity [7, 25]. Recently,
van der Pal et al. [36] noted that one in eight survivors of
pediatric cancers will develop severe cardiac disease (e.g.,
CHF) 30 years after the initial treatment with anthracyclines and radiation therapy. The current average life
expectancy for individuals with DS is 55 years, with many
living into their sixties and seventies [37]. It is not known
whether the cumulative incidence of cardiac adverse events
associated with cardiotoxic chemotherapy is different
between long-term cancer survivors with DS and without
DS.
There have been hypotheses put forth on the factors that
may be involved during the pathogenesis of anthracyclinerelated cardiotoxicity in the DS setting. For example,
several lines of evidence suggest that individuals with DS
have mitochondrial dysfunction [38, 39]. Since anthracyclines can be toxic to the mitochondria, it is possible that
patients with DS may be more susceptible to cardiotoxicity
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due to underlying mitochondrial dysfunction [40]. The
increase in cardiac oxidative stress resulting from anthracycline chemotherapy may be less tolerated in patients with
DS compared to patients without DS, leading to increased
cardiotoxicity in the DS setting. The reduced capability to
tolerate oxidative stress may also contribute to the
increased sensitivity of AML–DS cells to the cytotoxic
effects of anthracyclines [6]. It is known that patients with
DS have high rates of congenital heart defects (CHDs).
While it is plausible that CHDs may impair the heart’s
ability to function properly while exposed to a cardiotoxic
stimulus, the presence of CHDs has not been shown to
impart a greater risk of cardiotoxicity in patients with DS.
None of the reviewed studies that take CHDs into account
have documented significant correlations between CHDs
and anthracycline-related cardiotoxicity in patients with
DS [4, 17, 18, 20, 28].
Despite the complications involved in reaching a
definitive consensus about anthracycline-related cardiotoxicity in the DS setting, the omnipresent message in most
of the published reports is that reduced anthracycline
exposure in patients with DS and AML is preferable. The
studies presented suggest that decreasing the anthracycline
dose in patients with DS did not decrease the therapeutic
efficacy of the treatment. Further prospective clinical trials
would contribute to solidifying a definitive answer to the
issue of anthracycline-related cardiotoxicity in patients
with DS and AML. There are multiple limiting factors that
make this clinical research difficult but also crucial to
continue the development and implementation of more
efficacious and less toxic treatment protocols for patients
with DS and AML.
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